Hepion Pharmaceuticals, Inc. (HEPA) — Financial statements
Income statement, balance sheet, and cash flow for Hepion Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.45↓96.2% | 12↓66.8% | 36↑7.1% | 33↑63.1% | 20 | |
| General & Administrative Expenses | 3↓55.8% | 7↓22.0% | 10↓7.1% | 10↑3.4% | 10 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 3↓55.8% | 7↓22.0% | 10↓7.1% | 10↑3.4% | 10 | |
| Other Expenses | 0.40 | 0.00↓100.0% | 3↑70.5% | 2 | 0.00 | |
| Operating Expenses | 4↓78.5% | 19↓60.1% | 48↑6.5% | 45↑49.6% | 30 | |
| Total Costs & Expenses | 4↓78.5% | 19↓60.1% | 48↑6.5% | 45↑49.6% | 30 | |
| Operating Results | ||||||
| Operating Income | -4↑78.5% | -19↑60.1% | -48↓6.5% | -45↓49.6% | -30 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.03↓54.2% | 0.07↓13.3% | 0.08↓10.0% | 0.09 | |
| EBITDA | -8↑44.5% | -15↑69.8% | -49↓9.5% | -45↓37.9% | -33 | |
| EBIT | -8↑44.7% | -15↑69.8% | -49↓9.4% | -45↓37.8% | -33 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.02↑98.0% | -1↓13078.2% | -0.01↑6.9% | -0.01↓14.7% | -0.01 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.02↓98.0% | 1↑13078.2% | 0.01↓6.9% | 0.01↑14.7% | 0.01 | |
| Non-Operating Income | 4↑192.3% | -4↓605.0% | 0.88↑311.5% | -0.41↓118.0% | 2 | |
| Other Income / Expenses | -4↓229.2% | 3↑459.0% | -0.89↓319.1% | 0.40↑117.5% | -2 | |
| Income Before Tax | -8↑48.8% | -16↑67.2% | -49↓9.4% | -45↓37.8% | -33 | |
| Income Tax Expense | 0.00↑100.0% | -3↓625.9% | -0.41↑85.8% | -3 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -8↑37.3% | -13↑73.0% | -49↓15.9% | -42↓29.0% | -33 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -8↑37.3% | -13↑73.0% | -49↓15.9% | -42↓29.0% | -33 | |
| Bottom-Line Net Income | -8↑37.3% | -13↑73.0% | -49↓7.9% | -45↓38.6% | -33 | |
| EPS (Basic) | -0.88↑99.2% | -107.35↑82.6% | -616.07↓3.6% | -594.75↓27.8% | -465.52 | |
| EPS (Diluted) | -0.88↑99.2% | -107.35↑82.6% | -616.07↓3.6% | -594.75↓27.8% | -465.52 | |
| Weighted Average Shares | 9↑7556.5% | 0.12↑54.7% | 0.08↑4.2% | 0.08↑8.4% | 0.07 | |
| Weighted Average Diluted Shares | 9↑7556.5% | 0.12↑54.7% | 0.08↑4.2% | 0.08↑8.4% | 0.07 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.